Aurobindo margin slips as costs outpace revenue; stock drops 5.38%
Net profit rose 1.99% only after a lower tax rate offset weaker operating profit, while margin trailed the 48-peer healthcare median by 3.58 percentage points.
Filed 21 May 2026, 19:40 IST · after market close · Aurobindo Pharma Ltd (AUROPHARMA)
Key takeaways
- Consolidated operating margin fell 1.58 percentage points YoY to 19.80% as expenses grew +7.74% against revenue growth of +5.62%.
- Net profit rose +1.99% YoY to Rs 920.84 cr, helped by a 3.73-percentage-point fall in the tax rate while other income was 8.88% of pre-tax profit.
- The stock fell -5.38% on the first trading day after results, versus a 1.02% median absolute move across its past eight result reactions.
Price around the results
Costs outpaced revenue in the consolidated Q4
Revenue grew +5.62% YoY, but expenses increased faster at +7.74%, reducing operating profit by -2.18% and narrowing operating margin by 1.58 percentage points. Sequentially, revenue rose +2.40% while expenses grew +3.32%, leading to a 0.71-percentage-point margin decline. Management said the sequential decline in US formulations revenue was mainly seasonal, while the base business remained stable despite lower transient product sales.
Lower tax rate softened the profit decline
Pre-tax profit fell -3.33% YoY as higher depreciation of +7.68% outweighed lower interest costs of -14.61%. Net profit still rose +1.99% because the tax rate fell 3.73 percentage points to 28.65%; sequentially, the tax-rate reduction was 3.38 percentage points. Other income contributed 8.88% of pre-tax profit, so reported profit growth was not driven only by operations.
Margin remains below its FY26 peak and sector peers
The 19.80% operating margin was below 21.38% in Q4FY25 and 20.51% in Q3FY26, although Q3 had briefly improved from 20.25% in Q2FY26. Aurobindo's margin was 3.58 percentage points below the 23.38% median for 48 healthcare peers that had reported the quarter. It ranked 15th from the bottom on this measure.
Management highlighted launches and biosimilar capacity
The company said it launched 12 products in the US during Q4FY26 and received approval for nine products. Management said Omalizumab and Denosumab filings are planned for Q2 2026, with the Denosumab EMA filing to be followed by an FDA filing. It also said TheraNym's 60 kL integrated mammalian cell-culture facility is planned for full commissioning by end-2026, while a second 60 kL unit is estimated to require USD 150-175 million of capital expenditure.
The market reaction was unusually negative for Aurobindo
The stock fell -5.38% on day one and was down -7.31% by day five, with trading volume at 2.41 times its reference level. This was materially larger than the 1.02% median absolute move across the past eight result reactions, six of which were negative. The stock's five-day relative performance was -6.16% against the benchmark.
Q4FY26 at a glance
Consolidated figures as filed with NSE — cross-checked against an independent source.
| Line item | Q4FY26 | Q3FY26 | QoQ | YoY |
|---|---|---|---|---|
| Revenue | ₹8,853 cr | ₹8,646 cr | +2.40% | +5.62% |
| Other income | ₹115 cr | ₹123 cr | -6.58% | +11.68% |
| Expenses | ₹7,101 cr | ₹6,873 cr | +3.32% | +7.74% |
| Operating profit | ₹1,753 cr | ₹1,773 cr | -1.16% | -2.18% |
| Operating margin (%) | 19.80% | 20.51% | — | — |
| Interest | ₹98 cr | ₹93 cr | +5.86% | -14.61% |
| Depreciation | ₹479 cr | ₹465 cr | +2.98% | +7.68% |
| Profit before tax | ₹1,291 cr | ₹1,339 cr | -3.58% | -3.33% |
| Tax | ₹370 cr | ₹429 cr | -13.75% | -14.46% |
| Net profit | ₹921 cr | ₹910 cr | +1.21% | +1.99% |
| EPS (₹) | ₹15.86 | ₹15.67 | +1.21% | +1.93% |
Operating margin of 19.80% compares with a Healthcare sector median of 23.38% across 48 peers that have reported Q4FY26.
How the stock reacted
| Window | Stock | vs NIFTY |
|---|---|---|
| Results day | -5.38% | -5.65% |
| Next session | -5.95% | — |
| 5 sessions | -7.31% | -6.16% |
| 15 sessions | -8.95% | — |
| 30 sessions | +2.35% | — |
Volume on the results session was 2.41× its 20-day average.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
This quarter
- The company launched 12 products in the US during Q4FY26.
Guidance & outlook
- Omalizumab and Denosumab filings are planned for Q2 2026, with Denosumab filing with EMA followed by FDA filing.
- CuraTeQ plans to align its expanded capacities for 2028 and beyond.
Expansion
- TheraNym Unit 1’s 60 kL integrated mammalian cell culture facility is planned for full commissioning by end-2026.
- TheraNym will build a dedicated greenfield Drug Substance facility, Unit 2.
- TheraNym Unit 2 will add 60 kL of mammalian cell-culture bioreactor capacity and downstream purification infrastructure.
- The TheraNym Unit 2 project is estimated to require USD 150–175 million of capital expenditure.
- The company spent net capex of USD 82 million in Q4FY26, mainly on capability enhancements and new business development.
New products
- Aurobindo launched 12 products in the US during the quarter.
New initiatives
- Aurobindo executed a supply distribution agreement with STADA for two EMA-approved biosimilars in selected EU territories.
- TheraNym executed an additional product schedule with MSD, expanding its existing contract manufacturing relationship.
- Under the MSD schedule, TheraNym will build, operate and supply drug substance to MSD.
- Aurobindo plans partnerships across growth markets to strengthen biosimilar commercialization and expand global reach.
Problems & risks
- US formulations revenue declined sequentially in Q4FY26 mainly because of seasonality.
- The US base business remained stable despite lower transient product sales.
What to watch
- Whether operating margin moves back above 19.80% after the 0.71-percentage-point QoQ decline.
- Progress on management's planned Q2 2026 Omalizumab and Denosumab filings.
- Whether the planned 60 kL TheraNym Unit 1 facility reaches full commissioning by end-2026.